(1R)-2-溴-1-(3-吡啶基)乙醇 | 391906-07-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: (1R)-2-溴-1-(3-吡啶基)乙醇
• 中文别名: 3-吡啶甲醇,a-(溴甲基)-,(aR)-
• 英文名称: (1R)-2-bromo-1-(3-pyridyl)ethanol
• 英文别名: (1R)-2-bromo-1-(3-pyridinyl)-1-ethanol；(AlphaR)-alpha-bromomethyl-3-pyridinemethanol；(1R)-2-bromo-1-pyridin-3-ylethanol
• CAS: 391906-07-3
• 化学式: C₇H₈BrNO
• 分子量: 202.051
• InChiKey: WTFAEVUHAUTLEF-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1R)-2-溴-1-(3-吡啶基)乙醇 在 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 以72%的产率得到2-(2-环氧乙烷基)吡啶
  参考文献：
  名称：

  2,4-thiazolidinediones as potent and selective human β3 agonists

  摘要：

  Methylsulfonamide substituted 2,4-thiazolidinedione 22c is a potent (EC50 = 0.01 muM, IA = 1.19) and selective (more than 110-fold over beta (1) and beta (2) agonist activity) beta (3) agonist. This compound has also been proven to be active and selective in an in vivo mode. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00063-4
• 作为产物：
  描述：

  3-(2-溴乙酰基)吡啶 在 硼烷 、 (R)-2-甲基-CBS-恶唑硼烷 作用下， 以 四氢呋喃 为溶剂， 以34%的产率得到(1R)-2-溴-1-(3-吡啶基)乙醇
  参考文献：
  名称：

  2,4-thiazolidinediones as potent and selective human β3 agonists

  摘要：

  Methylsulfonamide substituted 2,4-thiazolidinedione 22c is a potent (EC50 = 0.01 muM, IA = 1.19) and selective (more than 110-fold over beta (1) and beta (2) agonist activity) beta (3) agonist. This compound has also been proven to be active and selective in an in vivo mode. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00063-4

文献信息

• [EN] AMINO ALCOHOL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS D'AMINO-ALCOOL ET LEURS UTILISATIONS
  申请人：YUMANITY THERAPEUTICS INC

  公开号：WO2021247910A1

  公开（公告）日：2021-12-09

  The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

  本发明涉及在治疗神经系统疾病中有用的化合物。本发明的化合物，单独或与其他药用活性剂结合，可用于治疗或预防神经系统疾病。
• Azolidines as beta-3 adrenergic receptor agonists
  申请人：American Home Products Corporation

  公开号：US20020032222A1

  公开（公告）日：2002-03-14

  This invention provides compounds of Formula I having the structure 1 wherein, A, X, Y, Z, W, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  本发明提供了具有以下结构式的I号化合物的药物或药用盐，其中A、X、Y、Z、W、R1、R2、R3、R4、R5和R6的定义如前所述。这些化合物可用于治疗或抑制与胰岛素抵抗或高血糖（通常与肥胖或葡萄糖不耐受有关）相关的代谢紊乱、动脉粥样硬化、胃肠疾病、神经源性炎症、青光眼、眼压增高和频繁排尿，特别是在治疗或抑制2型糖尿病方面特别有用。
• Processes and intermediates useful in preparing beta3-adrenergic receptor agonists
  申请人：——

  公开号：US20030199046A1

  公开（公告）日：2003-10-23

  The present invention provides processes useful in the preparation of certain &bgr; 3 -adrenergic receptor agonists of the structural formula 1 the pharmaceutically acceptable salts thereof, and the hydrates of said pharmaceutically acceptable salts, wherein HET is as described herein. The invention further provides intermediates useful in the preparation of such agonists, and processes useful in the production of such intermediates.

  本发明提供了在制备特定的β3-肾上腺素受体激动剂的过程中有用的方法，其结构式如下：其中HET如本文所述。该发明还提供了在制备这类激动剂中有用的中间体，以及在生产这类中间体中有用的过程。
• [EN] SALT OF A PYRIDYL ETHANOLAMINE DERIVATIVE AND ITS USE AS A BETA-3-ADRENERGIC RECEPTOR AGONIST<br/>[FR] SEL D'UN DERIVE DE PYRIDYLE ETHANOLAMINE ET SON UTILISATION EN TANT QU'AGONISTE DU RECEPTEUR BETA-ADRENERGIQUE
  申请人：PFIZER PROD INC

  公开号：WO2003072571A1

  公开（公告）日：2003-09-04

  The present invention provides the tosylate salt of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol, the monohydrate of such salt, processes useful in the preparation of such salt and such monohydrate, pharmaceutical compositions comprising such salt, or such monohydrate, methods of treating ß3-adrenergic receptor-mediated diseases, conditions, and disorders in a mammal using such salt, such monohydrate, or such pharmaceutical compositions; and methods of increasing the content of lean meat in edible animals using such salt, such monohydrate, or such pharmaceutical compositions.

  本发明提供了(R)-2-(2-(4-噁唑-4-基-苯氧基)-乙基氨基)-1-吡啶-3-基-乙醇的对磺酸盐，该盐的单水合物，用于制备该盐和该单水合物的有用过程，包括该盐或该单水合物的药物组合物，使用该盐、该单水合物或该药物组合物在哺乳动物中治疗ß3-肾上腺素受体介导的疾病、症状和障碍的方法；以及使用该盐、该单水合物或该药物组合物增加食用动物中瘦肉含量的方法。
• Beta3 adrenergic receptor agonist crystal forms, processes for the production thereof, and uses thereof
  申请人：Pfizer Inc.

  公开号：US20030166686A1

  公开（公告）日：2003-09-04

  The present invention provides the tosylate salt of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol, the monohydrate of such salt, processes useful in the preparation of such salt and such monohydrate, pharmaceutical compositions comprising such salt, or such monohydrate, methods of treating &bgr; 3 -adrenergic receptor-mediated diseases, conditions, and disorders in a mammal using such salt, such monohydrate, or such pharmaceutical compositions; and methods of increasing the content of lean meat in edible animals using such salt, such monohydrate, or such pharmaceutical compositions.

  本发明提供了(R)-2-(2-(4-噁唑-4-基-phenoxy)-乙基氨基)-1-吡啶-3-基-乙醇的对磺酸盐，该盐的单水合物，用于制备该盐和该单水合物的有用工艺，包括该盐或该单水合物的药物组合物，使用该盐、该单水合物或该药物组合物治疗β3-肾上腺素受体介导的疾病、症状和障碍的方法，以及使用该盐、该单水合物或该药物组合物增加食用动物中瘦肉含量的方法。